The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 2,100 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

ARM’s hybrid 2024 Cell & Gene State of the Industry Briefing attracted over 800+ key stakeholders in the field. This event included ARM’s annual yearly update on the sector’s progress followed by two noteworthy sessions featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in the coming year.